Aurinia to Present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco
VICTORIA, British Columbia--(BUSINESS WIRE)--Dec 19, 2018--Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced its Chairman and Chief Executive Officer, Richard M. Glickman, will present a company overview at the 37 th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Thursday, January 10, 2019 at 10:00am PST, 1pm EST.
The presentation will be webcast live and can be accessed via the investor section of the Aurinia website, www.auriniapharma.com. A replay of will also be archived on the site following the event.
Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The company is currently developing voclosporin, an investigational drug, for the potential treatment of lupus nephritis, focal segmental glomerulosclerosis, and dry eye syndrome. The company is headquartered in Victoria, British Columbia and focuses its development efforts globally. For further information, see our website at www.auriniapharma.com.
We seek safe harbor.
View source version on businesswire.com:https://www.businesswire.com/news/home/20181219005177/en/
VP, Corporate & Public Affairs
Christopher Hippolyte, , 212-364-0458
KEYWORD: UNITED STATES NORTH AMERICA CANADA CALIFORNIA
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL RESEARCH OTHER SCIENCE SCIENCE
SOURCE: Aurinia Pharmaceuticals Inc.
Copyright Business Wire 2018.
PUB: 12/19/2018 08:00 AM/DISC: 12/19/2018 08:01 AM